{{distinguish|mildronate|medronate}}
{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462252636
| ImageFile = Minodronic acid.svg
| ImageSize = 150px
| ImageAlt = 
| IUPACName = (1-Hydroxy-2-imidazo[1,2-a]pyridin-3-yl-1-phosphonoethyl)phosphonic acid
| OtherNames = Minodronate; YM 529
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 40SGR63TGL
| IUPHAR_ligand = 3164
| CASNo = 180064-38-4
| CASNo_Ref = {{cascite|changed|??}}
| CASNo1 = 155648-60-5 
| CASNo1_Comment = (hydrate)
| CASNo1_Ref = {{cascite|correct}}
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 319144
| PubChem = 130956
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 115805
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VMMKGHQPQIEGSQ-UHFFFAOYSA-N
| SMILES = O=P(O)(O)C(O)(P(=O)(O)O)Cc1cnc2ccccn12
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H12N2O7P2/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18)}}
|Section2={{Chembox Properties
| C=9 | H=12 | N=2 | O=7 | P=2 
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt = }}
|Section5={{Chembox Pharmacology
| AdminRoutes = 
| Bioavail = 
| Metabolism = 
| HalfLife = 
| ProteinBound =
| Excretion = 
| Legal_status = 
| Legal_US = 
| Legal_UK = 
| Legal_AU = 
| Legal_CA = 
| PregCat = 
| PregCat_AU = 
| PregCat_US = }}
}}

'''Minodronic acid''' is a third-generation [[bisphosphonate]] drug.  It is approved for use in Japan for the treatment of [[osteoporosis]].<ref>{{cite journal | journal = Annual Reports in Medicinal Chemistry | volume = 45 | title = To Market, To Market - 2009.  16.  Minodronic acid | pages = 509–510 | author = Shridhar Hegde and Michelle Schmidt | year = 2009 | doi=10.1016/s0065-7743(10)45028-9}}</ref>  Its [[mechanism of action]] involves [[enzyme inhibitor|inhibition]] of [[farnesyl pyrophosphate synthase]] activity.<ref>{{cite journal | doi = 10.1358/dof.2002.027.10.701186 | last1 = Sorbera | first1 = L.A. | last2 = Castañer | first2 = J. | last3 = Leeson | first3 = P.A. | title = Minodronic Acid | journal = Drugs of the Future | year = 2002 | volume = 27 | issue = 10 | pages = 935–941}}</ref>

==References==
{{reflist}}

[[Category:Bisphosphonates]]
[[Category:Imidazopyridines]]


{{pharma-stub}}